Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers - Wikidata - awgldk - TriplyDB

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

http://www.wikidata.org/entity/Q24679375

about

Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.Simulating the mechanism of antimicrobial lipopeptides with all-atom molecular dynamics.Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Natural products to drugs: daptomycin and related lipopeptide antibiotics.Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.Daptomycin dose-effect relationship against resistant gram-positive organisms Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.In vivo pharmacodynamic activity of daptomycin Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis Methicillin-resistant Staphylococcal periprosthetic joint infections can be effectively controlled by systemic and local daptomycin.Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Emerging drugs for bacterial urinary tract infections.Pharmacoeconomics of treatment with the newer anti-Gram-positive agents.Update on daptomycin: the first approved lipopeptide antibiotic.In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Population pharmacokinetics of daptomycin Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection Outcomes analysis of daptomycin use in a community hospital.In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers Daptomycin: a review 4 years after first approval.Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever Advances in MRSA drug discovery: where are we and where do we need to be?Intravitreal daptomycin: a safety and efficacy study Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.Daptomycin in bone and joint infections: a review of the literature.Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Once-daily dosing in dogs optimizes daptomycin safety.

P2860

Q26786582-5903FCCB-983E-49F3-836D-98EA86600E7E Q33278984-D35B6A6D-7D50-402B-B028-5B97E78B477A Q33518268-F1A50BA2-31B9-4EEE-A72F-100C0145CABE Q33647074-076DB39A-BD9A-4929-BA1D-4059FAD952EE Q33981666-8D4CEF65-62C0-4E7D-8A98-D6B028D85DC3 Q34470713-835A4D96-D242-487C-82DE-9FD3A90B86F5 Q34882125-AC894397-1621-44DC-9571-1B2C629666DC Q34936759-28C3ED9C-E540-4AF4-A01E-9F33A0452242 Q35004882-4B578BE1-B2F6-40E8-AFB2-B5F1CCFC0452 Q35005549-A2D0F2B7-E957-4BA0-99C1-B401F1354D2A Q35091557-1D2D389A-2274-4147-935C-0A0DAB51CE15 Q35166807-B326C12D-E769-434F-93F7-621F50E32214 Q35617587-CAB2A40D-6D06-46BC-8CEB-2AAE0BB360EC Q35689273-86402664-DEA4-4159-AF14-A36FB1D79FC3 Q35910321-E0AF0B7E-976A-4C49-A3D7-0FD3A5513F5D Q35912780-319669B5-8D26-4556-991E-FFB1FBB90D2E Q35941476-51781CF5-CBDE-4B17-9067-16B42C7AC309 Q35959546-5C95DE09-21E4-455D-8FDF-D6D32F75D51B Q36150606-B7CBCB52-A7BD-4184-A1FE-80210C2F5B65 Q36458452-F16EA4D2-7BAE-4341-932C-55F1F1BBB71A Q36521880-D8717A81-8899-44FB-83F0-29626CA81D69 Q36558524-BCE80ED2-F4E3-414D-8E52-2BF85645BE07 Q36670451-4924946E-07D5-4BE3-9EF2-C7BAAC79645D Q36777821-14261AA8-C4F2-4B24-AEA3-21E605337013 Q36879791-1615CD7E-AC44-4B62-88F9-466E8ADF682C Q36895112-89BFFC98-AF5E-4AAC-BB0F-F354BF89048B Q36949468-B9306A6D-FA8F-4612-9B4A-DF21E94D9DEC Q36972980-BE4ECC3D-F975-4E75-AF0A-95662248F777 Q37072100-863ED7C7-A601-4BA8-89E2-3D89D2C891A7 Q37112508-BABB98CD-738E-4984-BFE5-64EA12358DCD Q37183015-AE728198-5532-4A4C-838F-ED4E1EC1A95C Q37258898-48F183B1-E33C-4A41-9166-41BC5BEA156C Q37319460-78268315-5881-41D2-A10F-381EEAEFF5A3 Q37544510-75ED8B95-5BC2-44BF-8E5E-B6A543E85C71 Q37639909-3F5638F0-AEA4-4882-9F92-092B6B191E64 Q38019839-8154066C-A99E-46FD-83AD-D85751EAD63F Q38088261-E5A0026E-CE0B-4D83-AC4F-F2830CA9D77A Q38164685-D918152D-0EE6-43B7-B827-56560B4EDD2C Q38895642-4F253C73-2BED-4085-B956-F1D28723445D Q39537062-8716CCC6-7F84-428A-854E-1C453401D8E4

P2860

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

http://www.wikidata.org/entity/Q24679375

description

1992 nî lūn-bûn

@nan

1992 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@ast

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@en

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@nl

type

label

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@ast

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@en

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@nl

prefLabel

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@ast

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@en

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@nl

P1433

Q24679375-6A5A89D3-7A25-4D6E-A15F-50720CD794B3

P1476

Q24679375-FF36C65E-0680-4F8A-9116-C7DAF9460FE0

P2093

Q24679375-1BB6231D-1FD1-4D5F-B17D-A6C6D6CAEC31

Q24679375-2E3CC52D-CB1A-4586-9F01-00C696881743

Q24679375-85025AC7-C4D3-4DA6-BB90-6B70440010C0

Q24679375-8CE9C4E8-3FEB-4072-85F2-847E51DBDC4A

Q24679375-C73ACA35-0641-40AF-800B-B57A49FAC2B2

P2860

Q24679375-05888E72-EC78-4672-A1E5-E1E3FC5F2DFF

Q24679375-253F1BA3-876F-4F92-8F80-47E0C0B270BF

Q24679375-298FE520-7D00-4B92-A641-A28205A1BD76

Q24679375-32868C4B-C50D-426D-BB68-6A96C975279D

Q24679375-32BA4122-18D2-4FC1-A55E-6725DA7BAE83

Q24679375-8DD25BFA-4655-4FEA-B137-15514D70A7AB

Q24679375-8FA7385B-D2B8-47BE-99E9-4A1F8A656E6A

Q24679375-912DB097-3390-4F25-BD6B-0C6065BD3A8A

Q24679375-9D9310E0-3542-4345-B2B3-3ABAA31A58CF

Q24679375-C98DF896-83A0-4710-9A3D-F330C9DD47BB

P304

Q24679375-2490968C-DE12-42B7-9B58-350BC4271CC7

P31

Q24679375-00447B57-668B-46C6-81C1-43F6CBA61254

P356

Q24679375-CF31979F-22AF-40D7-B6C7-350CA626FB93

P407

Q24679375-5E0B59A6-49FE-4748-977D-A6A3EBC0D792

P433

Q24679375-BCE4DC4E-6E3D-4626-AC1A-9CDBFB234A65

P478

Q24679375-AC3B0B2C-6832-44D1-9543-32DB6063DAEB

P577

Q24679375-96B08E38-5D0B-4B10-90F0-2724B2DB9AF0

P5875

Q24679375-82EF3F1A-9BE4-4A04-92A3-D830C3C1D538

P698

Q24679375-BF5E6D04-DDEF-4D19-9568-6C17E44B120E

P921

Q24679375-3FD225E8-58C6-479B-A35A-5D6DD5ECEBD0

P932

Q24679375-11E8F87F-7FF1-4AF4-B3FB-F34066D37967

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Single-dose pharmacokinetics a ...... ibiotic, in healthy volunteers

@en

P2093

E H Nyhart

http://www.w3.org/2001/XMLSchema#string

G L Brier

http://www.w3.org/2001/XMLSchema#string

H R Black

http://www.w3.org/2001/XMLSchema#string

J D Wolny

http://www.w3.org/2001/XMLSchema#string

J R Woodworth

http://www.w3.org/2001/XMLSchema#string

P2860

Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.

Noncompartmental determination of the steady-state volume of distribution.

Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies

Effect of protein binding of daptomycin on MIC and antibacterial activity.

Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.

Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032

Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

P304

318-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.36.2.318

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

1992-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21836387

http://www.w3.org/2001/XMLSchema#string

P698

1318678

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

188435

http://www.w3.org/2001/XMLSchema#string